Media

AAHI pioneers immune-enhancing platforms to provide potent, durable, broadly effective, and efficient vaccines and immunotherapies that are accessible to those who most need them.

NEWS & EVENTS

FILTER BY YEAR

AAHI Attends the World Vaccine Congress 2023 in Washington D.C.

March 27, 2023

AAHI

Local doctor helps develop potential tuberculosis vaccine. Here’s why it is so promising

March 7, 2023

The News Tribune

Thermostable TB Vaccine Found Safe and Immunogenic in Humans

March 7, 2023

Genetic Engineering & Biotechnology News

Breakthrough For Tuberculosis – One of The World’s Biggest Killers – As New Vaccine Shows Promise in Early Trials

March 6, 2023

Forbes

Temperature-Stable TB Vaccine Safe, Prompts Immune Response in NIH-Supported Study

March 6, 2023

National Institutes of Health

Page [tcb_pagination_current_page] of [tcb_pagination_total_pages]

First

Last

PRESS RELEASES

FILTER BY YEAR

The Access to Advanced Health Institute Reports Encouraging Results of First-In-Human Trial of Its Temperature-Stable Tuberculosis Vaccine Candidate

March 6, 2023

The Access to Advanced Health Institute Announces $3M Award to Develop an Intranasal Pan-Viral Countermeasure against Respiratory Viruses

February 15, 2023

The Access to Advanced Health Institute Announces $9.9M Award to Develop a Nasal Spray Influenza RNA Vaccine Through Phase 1 Clinical Trials

February 6, 2023

AAHI Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature

November 2, 2022

AAHI to Present Novel Applications of Its Unique Self-Amplifying RNA Vaccine Platform at the 10th International mRNA Health Conference

November 1, 2022

Page [tcb_pagination_current_page] of [tcb_pagination_total_pages]

First

Last